

Resource Summary Report

Generated by [NIF](#) on Sep 18, 2026

MPP 89

RRID:CVCL_1427

Type: Cell Line

Proper Citation

ICLC Cat# HTL00012, RRID:CVCL_1427

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1427

Proper Citation: ICLC Cat# HTL00012, RRID:CVCL_1427

Description: Cell line MPP 89 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Pleural epithelioid mesothelioma

Defining Citation: [PMID:10232421](#), [PMID:20164919](#), [PMID:22460905](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31395879](#), [PMID:35839778](#)

Comments: Population: Caucasian., Part of: TCGA-110-CL cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: MPP 89

Synonyms: MPP-89, MPP89

Cross References: CLO:CLO_0007858, CLO:CLO_0037115, CLDB:cl5400, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, BioSample:SAMN10988144, cancercellines:CVCL_1427, Cell_Model_Passport:SIDM00222, ChEMBL-Cells:ChEMBL3308241, ChEMBL-Targets:ChEMBL2366357, Cosmic:908150, Cosmic:1995512, Cosmic-CLP:908150, DepMap:ACH-000319, EGA:EGAS00001000978, GDSC:908150, GEO:GSM887341, GEO:GSM888417, GEO:GSM1670132, ICLC:HTL00012, LiGeA:CCLE_327, LINCS_LDP:LCL-1229, Pharmacodb:MPP89_964_2019, PRIDE:PXD030304,

Progenetix:CVCL_1427, PubChem_Cell_line:CVCL_1427, Wikidata:Q54906515

ID: CVCL_1427

Vendor: ICLC

Catalog Number: HTL00012

Record Creation Time: 20220427T220820+0000

Record Last Update: 20260913T004921+0000

Ratings and Alerts

No rating or validation information has been found for MPP 89.

No alerts have been found for MPP 89.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 4 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Bonsignore G, et al. (2025) Unraveling BOLD-100 synergistic potential in pleural mesothelioma treatment: an in vitro study. Investigational new drugs, 43(3), 634.

Pandey GK, et al. (2023) Genetic screens reveal new targetable vulnerabilities in BAP1-deficient mesothelioma. Cell reports. Medicine, 4(2), 100915.

Barbarino M, et al. (2020) PRMT5 silencing selectively affects MTAP-deleted mesothelioma: In vitro evidence of a novel promising approach. Journal of cellular and molecular medicine, 24(10), 5565.

Kolluri KK, et al. (2018) Loss of functional BAP1 augments sensitivity to TRAIL in cancer cells. eLife, 7.